Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0004153 (atherosclerosis)
 77,401 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A variety of lipids, lipoprotein (Lp) lipids and APO-Lp were measured in 72 patients of both sexes suffering from cerebrovascular arteriopathy and compared with a control group matched for age and sex. The best discriminators by univariate analysis were serum concentrations of APO-AI, followed by APO-AII, high density lipoprotein phospholipids and HDL cholesterol (HDL-C). Low density lipoprotein cholesterol and serum APO-B values were lower in the patients than in the controls. With APO-AI only, patients and controls could be classified with 88-91% certainty. By combination of some of the variables which were selected by a stepwise discriminant analysis, several models were calculated resulting in 93-97% segregation of patients from controls. By multivariate analysis, APO-AI, APO-AII, HDL-C, and triglycerides in combination with the blood pressure or the body weight index were independent variables (in a mathematical sense). By comparing the present data with published results of previous studies it is concluded that cerebral atherosclerosis differs from other forms of atherosclerosis by several major risk indicators.
 ...
PMID:Apolipoproteins AI, AII and HDL phospholipids but not APO-B are risk indicators for occlusive cerebrovascular disease. 309 38

Seventeen patients with familial hypercholesterolemia (9 males and 8 females) were treated with 1000 mg deoxycholic acid or placebo daily during 2 weeks in a double-blind, randomised cross-over fashion. A wash-out period was held between the two periods of therapy. Clinical chemical parameters, lipoprotein cholesterol and apolipoproteins were measured before and after each period. Low density lipoprotein cholesterol was reduced by 7.5% and LDL-apo B by 5.6%. Only the latter change was significantly different from the corresponding changes in the placebo period (P less than 0.05). High density lipoprotein cholesterol did not change. Apolipoprotein A-I decreased by 4% (P less than 0.05). Apolipoprotein A-II did not change. While taking deoxycholic acid, most patients had abdominal discomfort and/or diarrhoea. The serum transaminases increased in 7 patients taking this drug and in none while taking a placebo. We conclude that this therapy is of little value in hypercholesterolemic patients.
Atherosclerosis 1986 Oct
PMID:Effect of deoxycholic acid on lipoprotein and apolipoprotein levels in patients with familial hypercholesterolemia. 353 14

Hypercholesterolemia is an important atherogenic risk factor in type II diabetes, and although coronary artery disease (CAD) is frequent in these patients, it is not known whether cholesterol and lipoprotein metabolism differ in patients with (CAD+) and without CAD (CAD-). Our aim was to study cholesterol metabolism and lipoprotein kinetics in mildly hypercholesterolemic type II diabetic men with and without CAD under similar dietary conditions. Despite similar serum and lipoprotein cholesterol levels, and kinetics of total and dense LDL apo B, light and dense LDL particles were cholesterol-enriched only in CAD+ subjects. Apolipoprotein A-II level was lower in CAD+ than in CAD- subjects (27.1 +/- 0.7 versus 30.9 +/- 0.7 mg/dl, P < 0.05), HDL cholesterol and apolipoprotein A-I kinetics were similar in the two groups. Cholesterol absorption was significantly higher in the CAD+ versus CAD- subjects (27 +/- 2 versus 20 +/- 3%, P < 0.05). In multiple logistic stepwise regression analysis with CAD as the dependent variable, cholesterol absorption efficiency and serum plant sterol/cholesterol proportions were the only variables significantly associated with CAD. In conclusion, in mildly hypercholesterolemic type II diabetic patients, the only metabolic parameter differentiating CAD patients from non-CAD ones was significantly higher cholesterol absorption efficiency in the coronary patients, which could contribute to the finding of the atherogenic cholesterol-rich dense LDL subfraction in these patients. Thus, a treatment causing cholesterol malabsorption by sitostanol alone or in combination with statin could be beneficial in these patients.
Atherosclerosis 1996 Oct 25
PMID:Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. 890 58